PDCD1 and metastatic melanoma: Nivolumab, a human monoclonal anti-PD-1 antibody, has been approved for use in unresectable or metastatic melanoma [80], metastatic NSCLC [81], Hodgkin’s lymphoma [82], and hepatocellular carcinoma [83].